NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has increased by 50.7% and is now trading at $4.37. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cyclerion Therapeutics.

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cyclerion Therapeutics.

Cyclerion Therapeutics Inc (NASDAQ:CYCN) posted its earnings results on Monday, May, 4th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.14. The company had revenue of $1.01 million for the quarter. Cyclerion Therapeutics had a negative net margin of 1,917.30% and a negative return on equity of 96.31%. View Cyclerion Therapeutics' earnings history.

News articles about CYCN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutCyclerion Therapeutics.

Cyclerion Therapeutics saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 1,300,000 shares, a decrease of 13.3% from the April 15th total of 1,500,000 shares. Based on an average daily volume of 406,000 shares, the short-interest ratio is presently 3.2 days. Currently, 5.5% of the shares of the stock are short sold. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Prothena (PRTA), Beyondspring (BYSI), Passage Bio (IMRA), Catalyst Pharmaceuticals (CPRX), Dynavax Technologies (DVAX), Satsuma Pharmaceuticals (STSA), Fulcrum Therapeutics (FULC), Neoleukin Therapeutics (NLTX), Calithera Biosciences (CALA), RAPT Therapeutics (RAPT), Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX), Puma Biotechnology (PBYI), Syros Pharmaceuticals (SYRS) and Seres Therapeutics (MCRB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Ovid Therapeutics (OVID), Galmed Pharmaceuticals (GLMD), Lexicon Pharmaceuticals (LXRX), Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD) and Agenus (AGEN).

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Cyclerion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include MFN Partners Management LP (8.75%), BlackRock Inc. (5.73%), State Street Corp (1.94%), AWH Capital L.P. (1.17%), Geode Capital Management LLC (1.16%) and AQR Capital Management LLC (0.59%). Company insiders that own Cyclerion Therapeutics stock include Amy W Schulman, Andreas Busch, Mark G Currie and William Huyett. View institutional ownership trends for Cyclerion Therapeutics.

CYCN stock was sold by a variety of institutional investors in the last quarter, including AWH Capital L.P., Horizon Kinetics Asset Management LLC, BlackRock Inc., New York State Common Retirement Fund, Alambic Investment Management L.P., UBS Group AG, and First Trust Advisors LP. Company insiders that have sold Cyclerion Therapeutics company stock in the last year include Mark G Currie, and William Huyett. View insider buying and selling activity for Cyclerion Therapeutics.

CYCN stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Sphera Funds Management LTD., Invesco Ltd., Ensign Peak Advisors Inc, Geode Capital Management LLC, Parametric Portfolio Associates LLC, AQR Capital Management LLC, and Wells Fargo & Company MN. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Amy W Schulman, Andreas Busch, and Mark G Currie. View insider buying and selling activity for Cyclerion Therapeutics.

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $4.37.

Cyclerion Therapeutics has a market capitalization of $121.29 million and generates $4.51 million in revenue each year.

The official website for Cyclerion Therapeutics is www.cyclerion.com.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]